Zydus Lifesciences Limited — FDA Warning Letter, 2026-06-02: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: FDA issued a Warning Letter to Zydus Lifesciences Limited on 2026-06-02 citing: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-722576-06022026
Argus analysis
Zydus Lifesciences Limited (MARCS-CMS 722576, FEI 3005430968) received an FDA Warning Letter dated June 2, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 9, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Zydus Lifesciences Limited MARCS-CMS 722576 — June 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-92 Product: Drugs Recipient: Recipient Name Dr. Sharvil Patel Recipient Title Managing Director Zydus Lifesciences Limited Near Vaishnodevi Circle, S. G. Highway Ahmedabad 382481 Gujarat India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-92 June 2, 2026 Dear Dr. Patel: Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of prescription drug products. FDA has reviewed the records you submitted in response to our November 7, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following: 1. Your firm failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined, as appropriate, and failed to test samples for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84). Your firm manufactures prescription (b)(4) drug products containing talc. (b)(4) USP is composed of more than (b)(4) % talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled. 1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4) , potentially linked to asbestos contamination of the talc. 3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or (b)(4) area). Your product is also labeled for use in (b)(4) . Your drug product, (b)(4) USP, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inha…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Zydus Lifesciences Limited had FDA enforcement actions before?
- Yes. Argus HQ has recorded 4 total FDA actions tied to Zydus Lifesciences Limited: 1 warning letter, 2 recalls, and 1 approval record.
- What FDA violations was Zydus Lifesciences Limited cited for?
- The FDA Warning Letter to Zydus Lifesciences Limited (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Zydus Lifesciences Limited?
- FDA issued the letter (MARCS-CMS 722576) on 2026-06-02 and posted it publicly on fda.gov on 2026-06-09.
- Is the FDA warning letter to Zydus Lifesciences Limited publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zydus-lifesciences-limited-722576-06022026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Zydus Lifesciences Limited — FDA Warning Letter, 2026-06-02: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-zydus-lifesciences-limited-2026-06-02-cgmp
"Zydus Lifesciences Limited — FDA Warning Letter, 2026-06-02: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-zydus-lifesciences-limited-2026-06-02-cgmp.
Argus HQ Research. "Zydus Lifesciences Limited — FDA Warning Letter, 2026-06-02: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-zydus-lifesciences-limited-2026-06-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_zydus_lifesciences_limited_2026_06_02_cgmp_2026,
title = {Zydus Lifesciences Limited — FDA Warning Letter, 2026-06-02: Request for Records/CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-zydus-lifesciences-limited-2026-06-02-cgmp},
note = {Accessed: July 13, 2026}
}